Immune phenotype in children with therapy-na&iuml;ve remitted and relapsed Crohn&rsquo;s disease

doi:10.3748/wjg.v16.i47.6001

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 47

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2243)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

296

HTML

1644

Figures (1-2)

138

Tables (1-3)

165

Sum=2243

Dec 21, 2010 (publication date) through May 10, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 21, 2010; 16(47): 6001-6009
Published online Dec 21, 2010. doi: 10.3748/wjg.v16.i47.6001

Table 1 Clinical data and patient characteristics

	Control	Therapy-naïve (before conventional therapy)	First remission (with conventional therapy)	Relapse (before IFX therapy)	IFX therapy (before 2nd infusion)	IFX therapy (before 3rd infusion)
Clinical data
n (boys/girls)	15 (6/9)	14 (6/8)	10 (4/6)	12 (5/7)
Age (yr)	12 (8-16)	10 (8.5-13)	11.5 (9.5-15.5)	14 (11-16)	14.5 (11.5-16)	14.5 (12-16)
Body mass index (kg/m²)	19.5 (16.5-22.3)	13.9 (12.5-15.8)^d	18.6 (14.4-19.2)^c	17.4 (14.1-19.5)^a	18.8 (14.6-21.3)	19.25 (16.1-22.1)
Body weight (percentile)	58 (35-79)	13 (4-23)^d	24 (19-44)^c	21 (7-28)^a	23 (15-63)	35 (10-74)
Disease duration (mo)	-	10 (8.5-13)	10.5 (8.5-15.5)	11.5 (9.25-15)	12 (9.5-15)	12 (10-15)
Activity index (PCDAI)	-	45 (39-58)	0 (0-5)^f	45 (25-48)^j	20 (7-28)^g	13 (2-22)^l
Localization (n, montreal criteria)	-	L1 (1), L2 (2), L3 (11)	L1 (0), L2 (2), L3 (8)	L1 (1), L2 (2), L3 (9)
Laboratory data
White blood cell count (g/L)	7.9 (5.7-10.1)	12.4 (9.4-14.2)^b	11.7 (8.4-14.4)	10 (8.2-11.2)	7.9 (5.5-10.6)	6.7 (4.5-10.4)^e
Platelet (g/L)	346 (288-375)	657 (451-746)^b	442 (308-624)	479 (396-750)^b	392 (293-523)	383 (308-483)^e
Serum iron (μmol/L)	16 (14-21)	4 (2-12)^a	8 (4-10)^a	4 (2-7)^d	5 (4-7)^d	8 (6-8)^b^e
Serum albumin (g/L)	45 (44-49)	37 (34-39)^d	42 (42-45)^c	40 (36-41)^d	41 (38-45)^b	42 (38-45)^b
C-reactive protein (mg/L)	0 (0-1)	21 (5-65)^d	7 (2-11)^b^c	27 (9-55)^h, ^d	9 (3-11)^d	5 (1-14)^d^e

^aP < 0.05,

^bP < 0.01;

^dP < 0.01 vs control;

^cP < 0.05,

^fP < 0.01 vs therapy-naïve;

^hP < 0.01,

^jP < 0.01 vs first remission;

^eP < 0.05,

^gP < 0.05,

^lP < 0.001 vs relapse. IFX: Infliximab; PCDAI: Pediatric Crohn's disease activity index; L1: Small bowel; L2: Large bowel; L3: Small bowel and large bowel localization according to Montreal criteria[48].

Table 2 Prevalence and ratios of cellular members of adaptive immunity

Cell prevalence in parent population	Control	Therapy-naïve (before conventional therapy)	First remission (with conventional therapy)	Relapse (before IFX therapy)	IFX therapy (before 2nd infusion)	IFX therapy (before 3rd infusion)
CD4⁺ in PBMC	35.16 (24.81-47.79)	36.52 (18.61-44.06)	37.42 (22.27-44.26)	39.12 (24.15-51.18)	39.77 (27.71-50.30)	35.65 (24.31-48.81)
Activated in CD4⁺	5.92 (2.39-6.51)	10.61 (3.93-19.04)^a	5.03 (3.37-7.93)^g	7.84 (5.30-11.67)^a	7.24 (5.67-12.25)^a	9.98 (5.45-16.19)^b
Naïve in CD4⁺	64.57 (59.86-73.03)	63.36 (41.19-74.86)	61.31 (39.09-73.05)	66.31 (60.44-71.79)	64.47 (53.90-77.87)	58.11 (53.51-64.96)
Effector in CD4⁺	21.91 (13.94-33.96)	31.29 (22.80-55.78)^a	33.97 (28.54-39.44)^a	29.47 (26.54-36.19)^a	35.23 (27.74-40.36)^a	37.62 (35.74-45.24)^bⁱ
Naïve/effector ratio	2.73 (1.60-4.97)	1.57 (1.02-2.54)^a	1.43 (1.14-2.21)^a	2.34 (1.66-2.68)	1.79 (1.47-2.36)	1.52 (1.19-1.74)^a^e
Th1 in CD4⁺	16.19 (9.91-25.26)	6.49 (4.50-7.67)^d	12.89 (5.12-19.03)^c	10.9 (4.03-14.38)^a	12.73 (8.12-15.81)	18.87 (12.51-38.11)^e
Th2 in CD4⁺	4.59 (2.78-5.51)	4.7 (1.98-6.03)	5.06 (1.42-8.48)	3.97 (2.27-7.19)	4.61 (2.55-5.65)	4.46 (2.11-8.16)
Th1/Th2 ratio	3.98 (3.06-5.12)	1.60 (0.50-2.11)^d	1.95 (0.43-3.62)^b	2.68 (0.85-5.07)	2.68 (1.42-6.14)	3.25 (1.37-4.80)^e
Treg in CD4⁺	1.25 (1.10-2.37)	1.36 (1.09-2.48)	1.41 (1.07-3.50)	1.31 (1.16-2.63)	1.33 (1.07-2.99)	1.96 (1.47-3.77)^b^e

^aP < 0.05,

^bP < 0.01,

^dP < 0.01 vs control;

^cP < 0.05,

^gP < 0.01 vs therapy-naïve;

^eP < 0.05,

ⁱP < 0.01 vs relapse. Data are expressed as median (interquartile range). IFX: Infliximab; PBMC: Peripheral blood mononuclear cell; Activated (CD25⁺); Naïve (CD45RA⁺); Effector (CD45RO⁺); Th1: T helper 1 committed, CXCR3⁺; Th2: T helper 2 committed, CCR4⁺; Treg: Regulatory T lymphocytes, CD25^hiFoxP3⁺.

Table 3 Prevalence and ratios of cellular members of innate immunity

Cell prevalence in parent population	Control	Therapy-naïve (before conventional therapy)	First remission (with conventional therapy)	Relapse (before IFX therapy)	IFX therapy (before 2nd infusion)	IFX therapy (before 3rd infusion)
NKT in PBMC	1.39 (0.81-2.42)	0.7 (0.11-1.33)^a	0.74 (0.37-1.34)	0.72 (0.45-1.23)	0.73 (0.37-1.20)	0.83 (0.31-2.05)
NK in PBMC	3.17 (1.71-4.76)	1.73 (0.72-3.49)^a	1.98 (1.65-2.97)	1.95 (0.72-4.81)	2.14 (0.66-4.78)	2.45 (1.26-4.85)
DC in PBMC	0.61 (0.10-2.15)	1.05 (0.54-3.32)^a	1.16 (0.58-2.98)^a	1.45 (1.09-3.46)^a	0.86 (0.30-2.80)	0.82 (0.52-2.31)
mDC in DC	46.04 (37.14-52.30)	61.66 (45.37-72.74)^b	45.19 (37.83-56.68)^c	69.01 (40.11-74.79)^a^e	60.01 (48.03-68.50)^a	57.39 (37.19-64.14)^a^g
pDC in DC	27.38 (20.65-33.94)	19.26 (15.08-24.58)^a	21.61 (14.76-32.61)^a	18.33 (16.59-26.42)^a	19.03 (17.26-32.38)	27.39 (19.68-36.70)^g
mDC/pDC ratio	1.85 (0.44-1.46)	3.05 (2.32-6.11)^d	2.35 (1.80-9.10)^b^c	3.5 (1.74-7.79)^d	3.04 (2.03-4.65)^d	2.20 (1.66-5.54)^b^g
TLR-2 in DC	8.8 (4.14-17.35)	55.08 (37.27-57.94)^d	17.32 (6.32-32.54)^c	38.7 (19.31-54.59)^b^e	25.89 (5.69-60.43)	16.70 (2.29-42.61)^g
TLR-4 in DC	2.24 (0.90-2.78)	14.36 (6.26-19.20)^b	2.73 (1.35-7.21)^f	10.11 (2.29-19.55)^a^e	5.31 (2.81-13.42)	3.32 (0.10-6.05)^g
Monocyte in PBMC	2.01 (1.38-3.82)	8.57 (3.82-16.72)^b	5.96 (2.49-21.22)^a^c	7.3 (2.65-15.44)^a	5.58 (2.78-17.52)^a	5.31 (3.54-6.94)^a
TLR-2 in monocyte	16.44 (10.31-19.69)	29.65 (17.83-39.77)^a	20.92 (7.87-29.15)^c	20.63 (7.05-29.01)	19.89 (13.13-29.32)	18.52 (10.29-28.96)
TLR-4 in monocyte	7.17 (0.45-14.73)	14.59 (3.01-35.23)^a	4.43 (1.82-8.31)^c	10.39 (2.10-26.54)	8.26 (2.71-17.56)	6.30 (2.48-18.94)

^aP < 0.05,

^bP < 0.01,

^dP < 0.001 vs control;

^cP < 0.05,

^fP < 0.01 vs therapy-naïve;

^eP < 0.05 vs first remission;

^gP < 0.05 vs relapse. Data are expressed as median (interquartile range). IFX: Infliximab; PBMC: Peripheral blood mononuclear cell; NK: Natural killer, CD3^-CD161⁺; NKT: Natural killer T, CD3⁺6b11⁺; DC: Dendritic cell, Lin1-HLA-DR⁺; mDC: Myeloid dendritic cell, CD11c⁺; pDC: Plasmocytoid dendritic cell, CD123⁺; Monocyte (CD14⁺); TLR: Toll-like receptor.

Citation: Cseh A, Vasarhelyi B, Molnar K, Szalay B, Svec P, Treszl A, Dezsofi A, Lakatos PL, Arato A, Tulassay T, Veres G. Immune phenotype in children with therapy-naïve remitted and relapsed Crohn’s disease. World J Gastroenterol 2010; 16(47): 6001-6009
URL: https://www.wjgnet.com/1007-9327/full/v16/i47/6001.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i47.6001